German Medical Fraud

28 July 1996

German Negative List "Not Against Law"

The German government's exclusion of "uneconomic" drugs from the list of products prescribable for public-sector health fund patients is not an infringement of the Basic Law, the federal social court, the BSG, has decided.

Ruling that the only exceptions to the ban on prescribing embodied in the negative list were drugs "specified for a particular form of therapy," the court thus rejected a case brought by a Cologne drug company, 98% of whose sales were of drugs used in various forms of enzyme therapy before the introduction of the negative list. These drugs were assessed as being "partially" no longer prescribable when the list was launched because of their composition.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight